mTOR in podocyte function: Is rapamycin good for diabetic nephropathy?

Comment on: Inoki K, et al. J Clin Invest 2011; 121:2181-2196 and Gödel M, et al. J Clin Invest 2011; 121:2197-2209

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell cycle (Georgetown, Tex.) Tex.), 2011-10, Vol.10 (20), p.3415-3416
Hauptverfasser:	Lu, Min-Kan, Gong, Xing-Guo, Guan, Kun-Liang
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Binding Biology Bioscience Calcium Cancer Cell Cycle Diabetic Nephropathies - drug therapy Diabetic Nephropathies - metabolism Landes Mechanistic Target of Rapamycin Complex 1 Mice Mice, Knockout Monomeric GTP-Binding Proteins - metabolism Multiprotein Complexes Neuropeptides - metabolism Organogenesis Podocytes - metabolism Podocytes - physiology Proteins Proteins - antagonists & inhibitors Proteins - metabolism Ras Homolog Enriched in Brain Protein Signal Transduction - physiology Sirolimus - pharmacology Sirolimus - therapeutic use TOR Serine-Threonine Kinases - metabolism Tuberous Sclerosis Complex 1 Protein Tumor Suppressor Proteins - genetics Tumor Suppressor Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Comment on: Inoki K, et al. J Clin Invest 2011; 121:2181-2196 and Gödel M, et al. J Clin Invest 2011; 121:2197-2209
ISSN:	1538-4101 1551-4005
DOI:	10.4161/cc.10.20.17686